Presentations to Highlight MRIdian Clinical Implementation and its Role in On-table Adaptive Therapy
CLEVELAND – ViewRay™, makers of the world's first and only MRI-guided radiation therapy system, announced today that the company will showcase its MRIdian System at the 3(rd) ESTRO Forum, the annual meeting of the European Society for Radiotherapy and Oncology, being held April 24-28, 2015 in Barcelona, Spain.
On April 27 at 1:15 p.m. CET in Room 114, ViewRay will host a Symposium titled "MRI-Guided Radiation Therapy: On-Table Adaptive Therapy is now a Reality", which will feature presentations from faculty at the first three MRIdian centers: Siteman Cancer Center at Washington University and Barnes-Jewish Hospital; UCLA Health, Jonsson Comprehensive Cancer Center; and University of Wisconsin, Carbone Cancer Center.
As part of this year's ESTRO meeting two podium presentations will highlight experience with the MRIdian System. The first is a presentation titled, "On-board MR Image Guidance for Adaptive Therapy," given by Rojano Kashani, Ph.D., Instructor in Radiation Oncology at the Washington University School of Medicine, which will take place during the Adaptive Radiation Therapy portion of the Joint Symposium on Proffered Papers on Saturday, April 25 at 2:45 p.m. CET in Room 117. The second presentation titled "Clinical Implementation of online MR-guided adaptive radiotherapy for abdominopelvic malignancies," given by Jeffrey R. Olsen, M.D., Assistant Professor of Radiation Oncology at Washington University School of Medicine, will take place during the Physics 5: New Technology and its Clinical Implementation session on Sunday, April 26 at 10:30 a.m. CET in Room 112.
ViewRay will be exhibiting at booth 5100 where attendees can hear firsthand clinical experience from users at Washington University School of Medicine and UCLA as they discuss MRIdian's unique high soft tissue contrast, MRI alignment, on-table adaptive treatments and real-time MRI tracking. Presentations will take place at various times on Saturday, Sunday and Monday. A detailed schedule of presenters, dates and times is available at http://www.viewray.com/estro_2015.htm.
"The ability to adapt treatment in real-time to changes and movement in a patient's anatomy is a significant step in radiation oncology and is being made possible today with the MRIdian System," said Chris A. Raanes, ViewRay president and CEO. "We're excited that our users can share their experience with this year's ESTRO attendees who may be looking to integrate MR-guidance and adaptive treatment into their patient offerings."
Visitors to the company's booth can also receive a system demonstration and simulate an entire treatment on in-booth treatment planning stations. They'll be able to experience the quality of MRIdian's soft-tissue imaging and understand the value it can provide in on-table adaptive treatment planning.
ViewRay Incorporated of Cleveland, Ohio, is a privately held medical device company developing advanced radiation therapy technology for the treatment of cancer. The MRIdian system provides continuous soft-tissue imaging during treatment, using MRI-guided radiation therapy, so that clinicians are able to see where the actual radiation dose is being delivered and adapt to changes in the patient's anatomy. For more information, visit http://www.viewray.com.
ViewRay acknowledges the contribution of the State of Ohio, Department of Development and Third Frontier Commission, which provided funding in support of the MRI Technology Enabling Expansion of MRI into Radiotherapy Guidance Project.
SOURCE ViewRay Incorporated
CONTACT: Michael Saracen, Senior Director, Marketing, ViewRay Incorporated, Phone: +1 440.703.3210, ext. 200, Email: email@example.com
Web Site: http://www.viewray.com